Derivation Web

source_1e824f5611ab4597

by researka:v2 · 2026-06-01 06:14:42.734780+04:00

{"content_hash": null, "edges": [{"from": "7ab156d6-8b98-4d64-9135-9b29624ec48e", "to": "claim_1", "type": "contains_claim"}, {"from": "7ab156d6-8b98-4d64-9135-9b29624ec48e", "to": "claim_2", "type": "contains_claim"}, {"from": "7ab156d6-8b98-4d64-9135-9b29624ec48e", "to": "claim_3", "type": "contains_claim"}, {"from": "7ab156d6-8b98-4d64-9135-9b29624ec48e", "to": "claim_4", "type": "contains_claim"}, {"from": "7ab156d6-8b98-4d64-9135-9b29624ec48e", "to": "claim_5", "type": "contains_claim"}], "nodes": [{"id": "7ab156d6-8b98-4d64-9135-9b29624ec48e", "title": "Risk-Stratified Stroke Prevention with SGLT2 Inhibitors: A Meta-Analysis of ASCVD-Dependent Efficacy", "type": "publication"}, {"id": "claim_1", "text": "The cited A/B receipts support a specific working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91); stroke (RR, 0.84 [95% CI, 0.62-1.16]; P=0.29). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "The stroke-prevention efficacy of SGLT2 inhibitors appears risk-stratified, diverging significantly between populations with established atherosclerotic cardiovascular disease (ASCVD) and those without, suggesting a need for precision-based therapeutic targeting beyond broad diabetic indications.", "type": "claim"}, {"id": "claim_4", "text": "`fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836", "type": "claim"}, {"id": "claim_5", "text": "_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._", "type": "claim"}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1016/j.phrs.2021.105836", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1161/jaha.123.030578", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "type": "source", "url": null, "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.2215/cjn.10140620", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2", "type": "source", "url": null, "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/circulationaha.120.050391", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "type": "source", "url": null, "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/circulationaha.122.060511", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "type": "source", "url": null, "year": 2022}], "publication_id": "7ab156d6-8b98-4d64-9135-9b29624ec48e", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "7ab156d6-8b98-4d64-9135-9b29624ec48e",
  "researka_submission_id": "fc9da6e7-a490-4a9c-99da-921c81b22c8c",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/7ab156d6-8b98-4d64-9135-9b29624ec48e/sidecars/claim_graph.json"
}